Navigation Links
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
Date:4/23/2009

n, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until approved for marketing by the FDA. Similar restrictions apply in other countries.

About Study 204

In the Phase IIb study (previously disclosed as Study 204), 278 treatment naive, genotype 1 patients were randomized with the following patient demographics: mean age 48.8 yrs, 61.1% male, 30% African-American or Latino, 80.7% viral load ¿400,000 IU/mL and 82.1 kg mean weight. Week (TW) 60 efficacy and safety results for the intention-to-treat (ITT) population are shown in the table above.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential for taribavirin in the treatment of hepatitis C, and the continuing role of ribavirin or taribavirin in the treatment of hepatitis C, that are based on management's current expectations and involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the clinical development of new products, regulatory approval processes, that results from week 60 in the phase IIb clinical trial are not necessarily predictive of the entire phase IIb trial or a phase III trial, and other risks as set forth under the caption Risk Factors in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated h
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
3. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
6. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Just as fitness and health professionals ... own financial and marketing strength to be important as ... the next level by using the most powerful communication ... Broadcast, Call Tracking and SMS texting solutions . ... messages are quickly become integral in marketing and communication ...
(Date:7/24/2014)... Kathleen Doheny HealthDay ... Parents of obese children often don,t view their kids as ... inactivity, according to a new study. The children of ... obesity clinic at the Hasbro Children,s Hospital in Providence, R.I. ... very good," said study researcher Dr. Kyung Rhee, now an ...
(Date:7/24/2014)... July 24, 2014 This year the ... Light Electric and Jackson National Life, will be held on ... 7 am, the Kids Fun Run at 7:50 am, the ... at 9 a.m. , “The Walk to End Alzheimer’s unites ... dedication in the fight against this devastating disease, “stated Linda ...
(Date:7/24/2014)... A new study led by the Translational Genomics ... bacteria, viruses and the immune system during HIV infection. ... potential to infect others based on their blood ... virus in their semen despite having low levels in ... of the virus can be found in different parts ...
(Date:7/24/2014)... As the age of marriage and ... as a way to ensure future family building options ... advancing reproductive age. Vitrification technology, a fast freeze method ... technology that allows a woman to have multiple eggs ... which are then stored for future use. When circumstances ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4
... research leads to groundbreaking conclusions. Valuable research data all ... unexposed to the light of day, and unused by ... dark data, is now being set free with the ... Research Notes, a new open access journal, is publishing ...
... NEW YORK, Feb. 26 On February 25, ... DGMS.PK) (http://www.digimedical.com ),updated the investment community in ... in the interview include an overview of the,company ... opportunity,and upcoming milestones for which investors should watch., ...
... of UPMC has been selected to join an effort ... to collect and study information necessary to understand the ... called primary sclerosing cholangitis (PSC). , The Studies of ... effort initiated, funded and organized by The Musette and ...
... R.I. Adults and teens that underwent surgery as infants ... face to appear uneven still have a degree of facial ... Hasbro Childrens Hospital surgeon. , The study, published in the ... coronal synostosis, a type of craniosynostosis, in which the bones ...
... "It is not clear that the,benefits of ... or other effects such as dental fluorosis," according ... Fluoride chemicals are added to 2/3 of U.S. ... is found in dental products,supplements and virtually all ...
... Court, WILMINGTON, Del., Feb. 26 The following,statement ... W.Va., zinc smelter,class action lawsuit late Monday. The statement ... Mobley., "We are extremely disappointed by the rulings ... the recent rulings and the earlier,jury verdicts. We believe ...
Cached Medicine News:Health News:Shining light on science's 'dark data:' New venture ensures a fuller scientific record 2Health News:WallSt.net (www.wallst.net) Updates Investment Community Through All-New Interview With digiMedical Solutions 2Health News:Children's Hospital 1 of 10 pediatric hospitals in US selected to study liver disease in kids 2Health News:Facial asymmetry persists despite surgery to correct congenital deformity 2Health News:Fluoride May Damage the Brain, New Report Says 2Health News:DuPont Responds to Spelter, W.Va. Lawsuit Rulings 2
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources Group ... the EU5 countries ( France , ... Spain and the ... of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) ... uptake of Relvar as a first-line LABA/ICS FDC in ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Calif., Nov. 17 Poniard Pharmaceuticals, Inc. (Nasdaq: ... randomized, controlled Phase 2 trial of picoplatin in patients ... indicated that picoplatin, given once every four weeks in ... has comparable efficacy to oxaliplatin, given in combination with ...
... , LAKE ZURICH, Ill., Nov. 17 ... improving blood collection, separation, safety and availability, announced today ... the Verax Platelet PGD® test as a quality control ... platelets prior to transfusion. Fenwal is the exclusive ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: